Objective: To review the evidence for the role of dietary modifications in alleviating chronic fatigue syndrome symptoms.
C hronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME), recently redefined by the Institute of Medicine as Systemic Exertion Intolerance Disease (SEID), 1 is a chronic multisystemic condition that severely affects daily life, impairing a person's ability to perform everyday tasks due to overwhelming fatigue, which in turn affects quality of life. [1] [2] [3] [4] [5] [6] For the purpose of this review, the term CFS will be used. Symptoms characteristic to CFS include immobilising fatigue, sleep disturbance, headaches and difficulty concentrating as well as muscular pain. 2, 5 The aetiology behind CFS is unknown, with new diagnostic criteria 1 and name (SEID)
aimed at improving diagnostic time as well as consolidating the focus of new research aimed at addressing the cause of CFS. 1, 3, 4, 6 Recent findings of an objective characteristic chemical signature for CFS are hoping to also prove useful in eliminating diagnostic uncertainty, highlighting CFS as a pattern of hypometabolic response to environmental stress. 7 CFS community prevalence is estimated to be 0.2% to 0.7% in the US and UK, 6, 8, 9 although valid epidemiological data is limited. 3, 10, 11 Not only is the individual and their quality of life affected but the community is as well. The economic impact of CFS within the limited Australian data available is estimated at $13,471 annually per case for the year 2000 for individual medical costs and time lost in productivity. 8 The overall annual direct and indirect economic costs are estimated at $525 million. 8 More recent US data suggest an annual direct and indirect cost estimate of $17-24 billion dollars. 12 Research into effective treatment of CFS symptoms is vital, particularly studies addressing treatment using dietary modification rather than pharmacological measures.
Previous reviews on CFS have not concentrated solely on the effectiveness of dietary modification as, to the knowledge of the authors, data specific to this research question is limited. 5, [13] [14] [15] Complementary and alternative medicine therapies were the focus of previously conducted CFS reviews, with some studies briefly discussing dietary modification among a vast range of other alternative and pharmacological therapies. 5, [13] [14] [15] This review highlights research in this field with specific focus on dietary modifications. By examining the current literature surrounding the topic, this review will identify effective dietary modifications for use. Due to the narrow extent of studies available, 5, [13] [14] [15] literature reviewed in this study is comprised of data on dietary modification by food, supplementation or dietary outcome assessment and its effect on alleviating the symptoms of persons with CFS across a range of study designs. Inclusion across a range of study designs effectively highlights the current state of evidence for this topic. This study reviews data on dietary modification in food or supplement form or dietary outcome assessment in relation to CFS. The research hypothesis stands on the alternative hypothesis that dietary modifications alone are useful in alleviating the symptoms of CFS.
Methods
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement protocol was used to inform the methods used in this systematic review 16 (see Supplementary File 1).
Data collection
The scientific databases Scopus, CINAHL Plus, Web of Science and PsychINFO were searched in May 2014 (1994-2014). A date limit was applied due to limited awareness and work surrounding CFS, with the first case definition only developed after 1988. 10 An updated database search was performed for the period of June 2014 to August 2016, limited only by date. The search terms, developed from the initially selected key words, medical subject heading (MeSH) terms and synonyms, were used within Boolean search strategies across the databases. The search terms included "chronic fatigue syndrome", "CFS", "myalgic encephalomyelitis", "diet" and "supplementation".
To systematically gather all available evidence, animal as well as human observational and experimental study designs were included if they met inclusion criteria parameters. The broad range of study designs were chosen to be included as the extent of research surrounding this topic is narrow.
Study selection
For inclusion in this review, studies needed to provide data on dietary outcomes assessment or modification in food or supplement form in relation to CFS and its symptoms, or a model of CFS and its accompanying symptoms. For those studies considering supplement use, the Therapeutic Goods Regulations 1990 17 was consulted, with a number of designated active ingredients excluded from inclusion in this review. This ensured the review held its focus on dietary modification rather than pharmacological measures. Studies were required to be published in the English language and were excluded if they were published more than 22 years ago. Only original studies were included, with editorials and letters excluded. Studies were selected ensuring that they met the inclusion criteria, had relevant findings and showed some level of validity through quality assessment methods.
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Relevant studies were selected from the pool of studies returned by the searches performed across each database by initially screening the title and abstract. For preliminary screening, if the title and abstract did not provide sufficient information or the abstract was unavailable the full study was screened. The subsequent full text studies were then reviewed to ensure they met the inclusion criteria, were primary studies and were not reviewing disproved treatment strategies such as homeopathy.
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Data extraction
Upon gathering data from the included primary studies, a standardised for an assessment of risk of bias within each included study and fostering systematic and objective quality rating assignment. The checklist addresses relevance, applicability, validity and bias. 20 These aspects of quality and bias are found within the summary table. Ethics approval of all included studies was also considered.
Study outcomes
The summary table was used to systematically extract data from each study included in the review in order to make clear comparisons and provide a brief overview of all studies. Results are reported according to prominent data themes that emerged from the review.
Results
Study retrieval
Across the identified databases, 435 potential primary research papers were identified (see Figure 1 ). Of these, 22 primary research papers were included in the systematic review.
Animal studies and polyphenols
Three animal studies were included examining the effect of differing polyphenols and their impact on induced CFS symptoms Full-text articles assessed for eligibility: 48
Full-text articles excluded: 21 articles did not meet inclusion criteria components, were not a primary study or were reviewing disproved treatment strategies i.e. homeopathy (21) Total number of studies included: 27 The effect of AMF oral administration in rats highlighted statistically significant increases in endurance through forced swimming compared to rats not administered with AMF (p<0.05) in the chronically fatigued groups. 22 Spleen cell proliferation was statistically significantly increased with AMF supplementation (p<0.05) as well as abnormal cytokine production levels being regulated (p<0.05) in chronically fatigued groups. 22 Daily EGCG oral administration highlighted a significant increase in endurance capacity during forced swimming and decreased postswim fatigue levels compared to the chronic fatigue rat group at 28 days (p=<0.05). Greater endurance and decreased post-fatigue levels were displayed with the administration of 100 mg/kg compared to 50 mg/kg (p<0.05).
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Use of EGCG prevented reductions in body weight and restored spleen and thymus induced hypotrophy compared to the chronic fatigue rat group (p<0.05), with significantly greater prevention of body weight reduction and spleen hypertrophy restoration using 100 mg/kg dose verse 50 mg/kg dose (p<0.05). 23 In an elevated plus maze learning task, administration of EGCG decreased initial transfer latency compared to the chronic fatigued group (p=<0.05). 23 Use of an oral dose of EGCG also showed favourable statistically significant changes in measures of oxidative and nitrosative stress and proinflammatory cytokine levels, factors that may contribute to fatigue development. [22] [23] [24] For the polyphenol naringin, differing oral doses were administered to mice treated with lipopolysaccharide (LPS) or brucella abortus (BA) antigen, which induced immunological fatigue. 24 Naringin use showed a statistically significant and dose-dependent decrease in the duration of immobility in immunologically induced fatigued mice (p<0.05) and a significant increase in mean tail withdrawal latency compared to BA or LPS injected mice (p<0.05). 24 A statistically significant dose dependant increase in reduced glutathione levels was also seen through naringin administration compared to BA or LPS injected mice (p<0.05). 24 Again, as seen with use of the other polyphenols, statistically significant favourable changes in measures of oxidative and nitrosative stress and a pro-inflammatory cytokine were highlighted.
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Dietary interventions and CFS symptom alleviation
Only one eligible study assessed a dietary intervention with reference to CFS symptoms alleviation. 4 The experiment applied a 24-week intervention of a low-sugar lowyeast diet (LSLY), with intention to treat analysis showing no statistically significant difference for the intervention and guideline based healthy eating control between the primary outcome measures. 4 Compliance was poor, and compliant analysis was performed only on baseline characteristics comparing those who completed their role in the experiment and those that did not.
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Dietary intake and poor vitamin or mineral status and CFS
Three studies examined dietary intake and associated correlations to CFS. [25] [26] [27] [28] Differing dietary intake patterns were highlighted through a descriptive observational study design, with findings of dairy and grain avoidance most prominent in the CFS cohort evaluated. 25 These dietary restrictions in many cases were reported to be undertaken due to provision of non-evidence based information and diagnostic testing from alternative therapy practitioners. 25 Very little correlation of abnormal biomarkers with inadequate nutritional intake in CFS patients was displayed in another descriptive observational study. 28 The findings continued in a consistent manner, highlighting through an analytical observational study that 95% had poor fibre intake and 70% had unhealthy fat, fruit, and vegetable intake measured through defined cut off limits from questionnaire assessment tools. 27 Yet, lifestyle factors including overweight and unhealthy dietary intake were not significantly associated with fatigue severity or functional impairment. 27 One study considered the vitamin status and direct association of CFS symptoms alleviation. The analytical observational study examined mean serum 25 OH vitamin D levels. Levels were highlighted to be moderately to severely suboptimal in CFS participants at 60.1% for those not taking supplements. This finding was statistically significantly lower over winter/spring (p<0.04) and summer/autumn (p<0.003) compared to the general population control study arm, 26 yet no observed relationship for alleviation of symptoms of CFS was seen.
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Supplements and CFS symptom alleviation
Three experimental studies examined use of single nutrient supplements. [33] [34] [35] Following on from the aforementioned serum 25 OH vitamin D analysis, an experimental trial investigated the use of an oral vitamin D3 supplement. 35 The measured outcomes from this trial pertinent to the review highlighted no statistically significant improvement for both fatigue or for the selected markers of inflammatory and oxidative stress. 35 Secondly, probiotic supplementation was examined finding no significant change. 33 Six of 15 participants in this study did report subjective improvement after the trial and statistically significant improvement was seen for the neurocognitive function measures (p=0.04), yet no significant changes in aerobic intestinal microflora were found. 33 Another study observed supplementation using D-ribose. 34 Significant improvement for energy levels between pre-and postenrolment in the compliant analysis was seen (p<0.0001, 95%CI 1.1-2.2) and 65.7% of participants indicated improvement in regard to their overall subjective feelings. 34 Regarding the experimental studies examining polynutrient supplements, one vitamin and mineral supplement study highlighted statistically significant improvements for before-and-after measurements of superoxide dismutase (SOD) antioxidant enzyme activity (p≤ 0.005). 31 Aspects of fatigue measures showed statistically significant improvement in fatigue itself (p=0.0009), sleep disorder (p=0.008), autonomic nervous system symptoms (p=0.018), headaches (p=0.0001), and subjective feelings surrounding infection (p=0.0002). 31 Some aspects of quality of life measures were also statistically significant including total physical function (p=0.053), physical role (p=0.031), pain (p=0.01), mental vitality (p=0.029) and mental health function scores (p=0.014). 31 Yet, in another study trialling a vitamin and mineral supplement no statistically significant relationship was seen. 32 Furthermore,
another study also experimentally addressed polynutrient supplementation seeing no statistically significant results with fatigue, disability and symptoms assessed through the primary measured outcomes. 30 Lastly, practices of mixed self-applied supplementation were observed in an analytical observational study. 29 Minimal changes in fatigue were shown over the follow-up period in response to a range of different self-applied therapies, including nutritional therapies. 29 A small number of the total cohort found a nutritional therapy useful, with ginseng found to be most helpful within users (56%). 29 Measured outcomes compared to effect of different nutritional therapies revealing inconsistent results. Magnesium (no specified dose) at six months was statistically significant with improvement in fatigue (p=0.002), yet at two years showed no significant relationship. 29 Calcium (no specified dose) was introduced by participants at six months to two years and showed statistically significant improvement in fatigue (p=0.01), yet was based on five participants.
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Fatty acids and CFS symptom alleviation
Three eligible studies regarding fatty acids were considered in relation to CFS symptoms. [36] [37] [38] In an analytical observational study a statistically significant reduction was shown in the CFS cohort for the omega three (n-3) to omega six (n-6) polyunsaturated fatty acid (PUFA) ratio (p= 0.0003) and eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (p=0.02). 36 A statistically significant positive relationship was also observed between n-3 to n-6 PUFA ratio and serum zinc (p=0.009), an indicator of the inflammatory response. 36 A statistically significant relationship between lowered n-3 PUFA and the expression of CD69 on activated T cells (p<0.05) was seen. 36 There was also a statistically significant positive relationship between the severity of CFS symptoms and certain n-6,PUFA, n-9 PUFA, oleic and palmitic acid (p<0.05) and a statistically significant negative relationship between n-3 to n-6 ratio and severity of CFS symptoms (p=0.027). 36 An essential fatty acid (EFA) supplement rich in EPA was individually examined in a case study. 37 Depression scores dropped from 27 at baseline to 3 at 16 weeks and the lateral ventricular volume of the brain had decreased at 16 weeks for the CFS participant. 37 Yet, another experimental trial of an EFA supplement verse a placebo supplement of sunflower oil showed no statistically significant difference in the RBC membrane fatty acid profile and symptoms scores between the intervention and control group.
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Tryptophan and glutamine amino acids and CFS
The amino acid tryptophan (Trp) and its potential role in CFS symptoms expression was examined in two studies. 39, 40 Within one, the selected CFS cohort displayed a significantly higher mean free (48%, p=0.0000) and total Trp (19%, p=0.0016).
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Serum free Trp to competing amino acids (CAA) ratio was significantly higher (43% p=0.0000) in the CFS cohort and the serum total Trp to CAA ratio was only significantly higher when co-varied with age and gender (p=0.0562). 39 Non-esterified fatty acid (NEFA) levels were significantly higher in the CFS cohort (p=0.0192), as was serum glucose (p=0.0058) and a slightly higher albumin concentration was also seen in the CFS cohort (p=0.0016). 39 Total CAA concentration though was not significantly different between the healthy control cohort and CFS cohort. 39 Within CFS participants if suggested serotonin parameters are applied there was a significant division in this cohort between those with high or normal serotonin status shown in free Trp (p=0.0002) and total Trp to CAA ratio (p=0.0195) and free Trp to CAA ratio (p=0.0000).
Within the second study, the amino acid blood sample findings were related to the research question. 40 These findings highlighted baseline free Trp was significantly lower in the CFS cohort (p=0.033) with no difference seen in neutral amino acid (NAA) concentration between the two groups. 40 Although lowered, there was no significant difference between groups for serum free Trp to NAA ratio and there was no difference for total Trp between the groups. 40 For the amino acid glutamine, the one experimental study revealed baseline measurements of participants with CFS had significantly lower mean plasma (p<0.001) and muscle (p=0.027) glutamine concentrations. 41 Post-trial outcomes for those with CFS in the intervention group receiving a glutamine supplement highlighted there was a significant increase in plasma and muscle glutamine concentration (p<0.05). 41 Those with CFS in the placebo group saw no significant increase in plasma or muscle glutamine concentrations (p>0.05). 41 Although supplementation increased stores of glutamine for CFS participants, those with CFS in the intervention group showed no statistically significant change in their five category questionnaire scores assessing symptoms, whereas CFS participants in the placebo group showed a significant decrease in the two categories of emotionality (p=0.02) and sleep problems (p=0.02). 41 Grouping CFS participants to show clinical improvement or no clinical improvement displayed both the intervention and control groups in each category. 41 The CFS participants in the group that showed no clinical improvement did display significant increases in mean plasma glutamine concentration (p=0.013) post trial as well as increases in their T-cell counts (p=0.010), T-helper cells (p=0.002) and a decrease in natural killer cell counts (p=0.019) and activated T-cells (p=0.015). 41 These outcomes oppose the reported baseline measures in the initial assessment, yet were not seen in the group that displayed clinical improvement.
Phosphate diabetes and consideration of differential diagnosis to CFS
Mean serum phosphate concentration was outlined to be significantly lower in the CFS cohort (p=0.01) but still within reference range in the single included analytical observational study. 42 Fourteen per cent of participants in the CFS cohort fulfilled diagnostic criteria for phosphate diabetes (PD), yet did not show a significant difference in symptoms when compared to those with CFS without a PD diagnosis. No statistically significant difference was seen between the intervention and control for mean overall values such as phosphate clearance, mean renal threshold phosphate concentration (TmPO4/GFR) and mean phosphate tubular re-absorption (PTR) rate values.
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Discussion
While this review found no definitive dietary modification for alleviation of the symptoms for individuals with CFS, some promising research was examined. The alternative hypothesis that dietary modifications are useful in alleviating the symptoms of CFS has not been substantiated within this review.
The included animal studies set a good platform for further human studies to be conducted in these areas of interest, with some encouraging significant results
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© 2017 The Authors highlighted through polyphenol use in mice or rats displaying induced fatigue. [22] [23] [24] Further studies in humans should consider supplementation of these isolated polyphenol compounds, as the results highlighted are unlikely to be obtained through normal dietary intake, for example, to obtain the effects seen from naringin around 50-200 mg/kg was administered. 24 Mean values of several fruit varieties high in naringin, including red grapefruit, blond grapefruit and sweetie fruit, showed around 50 mg/100 g of fresh weight from fruit identified, further impeded by its bioavailability in the food matrix. 43 Experimental LSLY dietary intervention was inconclusive. Although bias from poor compliance must be considered when interpreting these findings, compliance was not analysed against the measured outcome scores. Other reasons for such a finding may be potentially due to lack of power masking a result. 4 The results may have been clouded from the beginning as the studies hypothesis relied on dietary treatment of a suggested cause of CFS. Both the suggested cause and use of dietary modification for this suggested cause (LSLY diet) lacked any supporting scientific data, are controversial, and to date have not been linked directly to CFS. 4 Dietary intake patterns and poor vitamin or mineral status were not found to be associated with symptoms alleviation in the observational studies reviewed. [25] [26] [27] [28] Some important trends were found within these studies. One study notably observed in their selected CFS cohort that almost half of the dietary exclusions were made based on information from practitioners of alternative therapy or experience. 25 Those following this advice tended to have higher vitamin supplement intake, which may be detrimental, as discussed by Mursu et al., who noted that vitamin and mineral supplements increased total mortality risk in a cohort of generally healthy women with a mean age of 60 years. 44 Although this study displays a low level of evidence and had many limitations, 25 these trends regarding food avoidance and its influence on the diets of those with CFS are important to note for research and clinical practice to ensure the information being distributed and followed within CFS populations is correct and has a sound evidence base. Some supplementation recommendations were highlighted in light of other findings. Due to the nature of CFS with increased indoor dwelling, potential increased osteoporosis risk, and significantly lower mean serum 25-OH vitamin D, vitamin D intake through the diet and supplements should be considered for general health, regardless of the study findings. 26 The risk of chronic vitamin D deficiency mimicking CFS symptoms is also noted in two studies. 26, 28 One study continues, suggesting that an underlying pathological process may be responsible for abnormal biomarkers that showed very little correlation with inadequate nutritional intake, 28 an explanation that may also explain lifestyle factors of weight and dietary intake not significantly correlating with CFS symptoms. 27 Varied results were seen for the three experimental studies of single nutrient supplements. [33] [34] [35] For the study considering probiotic supplementation, it was not clear whether participant compliance was measured, and this may have influenced the inconsistent results. 33 In part, this result may have been seen as this trial might not have used a high enough dose or may have focused on too many different strains of bacteria at once, with Rao et al. 45 supporting this hypothesis, highlighting positive outcomes for anxiety and intestinal microflora using a higher single-strain probiotic dose. With this understanding of the included probiotic experiment, the potential relationship between the gut-brain axis and probiotic use and the gut microbiota for CFS is further reinforced and needs continued investigation. D-ribose was highlighted to have positive preliminary results, although further investigation should be made as the quality rating identified a potential conflict of interest. found that low-grade inflammation from heightened pro-inflammatory cytokines is characteristic in those with CFS and that antioxidant use may be helpful. These antioxidant/cytokine hypotheses align with the results seen in the animal models of polyphenols and their positive changes to induced fatigue and corresponding cytokine measured outcomes. [22] [23] [24] Mixed self-applied supplementation gave inconsistent results. Within the included analytical observational study, a list of different therapies used over the study duration was cited by noting the most commonly used therapies among participants. 29 This allows for many other potential treatments to have been in use concurrently to the listed therapies and dramatically decreases the accuracy of the results.
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Studies examining the role of fatty acids and CFS highlighted some positive outcomes, yet overall inconsistent results were seen. [36] [37] [38] One experimental study returned no significant results, although, the supplements used may have acted as a confounder to these results. 38 An EFA supplement containing a range of fatty acids -both n-3 and n-6 PUFA -was used, although the control supplement did not contain EPA and DHA. Mixing n-3 and n-6 PUFA could have negatively contaminated the results, 38 as highlighted by Maes et al. 36 who made observations regarding plasma free fatty acids. Although Puri et al. 37 did see significant results within their case study from a mixed EFA supplement (predominately n-3 PUFA), the previous hypothesis that n-6 PUFA may negatively affect results should still be taken into consideration for further research work. The positive outcomes seen from supplementation with predominately omega three fatty acids and observations in plasma free fatty acids could indicate the antiinflammatory role of omega three fatty acids imparting positive effects for inflammatory response in CFS as well as some symptoms reduction. 36 Findings again were inconsistent for those studies examining the role of tryptophan and glutamine amino acids and CFS. 39 It must be noted that within Vassallo et al. 40 observational study, the amino acid level investigation and results observed were reviewed, yet the other sub-sectors of this study were not relevant to the research question, having largely a neuroendocrine focus.
Glutamine amino acids findings showed experimentally that a CFS cohort at baseline displayed significantly lower mean plasma and muscle glutamine concentration, yet it is stated this is likely because of four participants' low values. 41 Post-trial outcomes show those with CFS in the intervention group saw a significant increase in plasma and muscle glutamine concentration as compared to CFS participants in the placebo group who saw no significant increases. This indicates the effectiveness of glutamine supplementation in increasing the body's supply of the amino acid.
Inconsistent results were highlighted, however, with use of categorisation of CFS participants into clinical improvement or no clinical improvement groupings, with a statistically significant increase for those who did not show clinical improvement post-trial in mean plasma glutamine concentration. It is proposed that a rise in only plasma glutamine for this group indicates an issue of glutamine regulation rather than decreased availability of glutamine in those with CFS.
Overall, glutamine supplementation increased body supplies of glutamine but demonstrated inconsistent effects on reported symptoms or clinical improvement.
Phosphate diabetes (PD) CFS cohort findings were contradictory and, although still within reference range, the CFS group did display a significantly lower mean serum phosphate concentration in the included analytical observational study. 42 Fourteen per cent of the CFS cohort met the PD diagnostic criteria, whereas no one in the healthy control group met the diagnostic criteria. Further studies should rule out the need for consideration of PD upon clinical presentation of CFS symptoms to ensure the diagnosis and management are correct.
Restricted primary research regarding this topic is a limitation of this review; the data is of lower quality and evidence level and the extent of research is narrow. 5, [13] [14] [15] Weaknesses exist within the body of evidence and add to the complexity of this topic. These include a variety of differing case definitions and diagnostic criteria for CFS, with the Institute of Medicine redefining CFS highlighting this weakness and aiming to address it. 1, 3, 10 Furthermore, a vast number of assessment tools and measures, displaying varying levels of validity, are in use for CFS. 1, 3 Relevant insights of study limitations are provided in this review, yet the aforementioned weaknesses meant that assessment of bias had to be carefully considered. Rather than a uniform assessment of bias being made across the included studies, an overview of individual assessments of limitations, validity and bias was made, provided in Supplementary File 2 (available online).
Limitations of relatively small sample sizes across much of the included primary research existed, with none of the included studies using an Australian cohort. Further research may benefit from including larger numbers and potentially multi-country study designs to ensure greater generalisability to the CFS population. 3 As is commonly evident in systematic reviews, some level of publication bias may be present as only published primary research met the strict inclusion criteria.
Not only is there a need for stronger study design and larger sample size use; there is also a need for research to assess varying whole-diet interventions being applied. The current body of evidence has more emphasis on supplementation or single nutritive factors, with only one primary research paper in this review including a specific dietary intervention trial. Individualised clinical recommendations still need to focus on evidence-based advice and dietary counselling, alongside general promotion of healthy eating habits across all medically tolerable food groups to also reduce other chronic disease risks and avoid development of deficiencies.
